Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04532164 · ClinicalTrials.gov registry record · Phase 3
Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
A Phase 3 study of Dermatitis, Photoallergic, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 137
- Enrollment target
- 1
- Study location
NCT04532164 is a Phase 3 study of Dermatitis, Photoallergic that has completed, run by Bayer. The registered enrollment target is 137 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04532164, a Phase 3 study of Dermatitis, Photoallergic, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 137 participants
- Enrollment target
- 1
- Study location
Study Summary
Allergic skin reaction can be produced by the combination of a chemical product applied to the skin and ultraviolet (UV) radiation (a type of invisible light that comes from the sun and other light sources and can hurt your skin and eyes) received by the person. The researchers in this study wanted to find out if cream V61-044 might cause an allergic skin reaction to sunlight when applied to the skin in healthy participants. Cream V61-044 (brand name: LOTRIMIN ULTRA) is an approved drug used to treat infections caused by fungi (small growing organisms such as mold, mildew, yeast or mushrooms). Participants joining this study underwent two study phases: in Induction phase, participants received the test cream and UV radiation twice a week for 3 weeks; after 10 days of rest, in Challenge phase participants received the test cream and UV radiation once again. In both phases, the test cream was applied to two test areas on the upper back of the participants and to one of the test area UV radiation was applied. Evaluation on the skin rash was conducted two days after each UV radiation.
Conditions Studied
Interventions
- DRUG Butenafine HCl 1% (BAY1896425) - Induction Phase
- DRUG Butenafine HCl 1% (BAY1896425) - Challenge Phase
Study Locations (1)
New Jersey
- - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2013-06-10 |
| Est. Completion | 2013-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04532164
The ClinicalTrials.gov registry entry for NCT04532164 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Photoallergic appearing as the primary indexed condition, and to 2 interventions - of which Butenafine HCl 1% (BAY1896425) - Induction Phase is the first listed.
NCT04532164 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04532164 about?
NCT04532164 is a clinical study titled "Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants". Allergic skin reaction can be produced by the combination of a chemical product applied to the skin and ultraviolet (UV) radiation (a type of invisible light that comes from the sun and other light sources and can hurt your skin and eyes) received by the person. The researchers in this study wanted ...
What is the current status of trial NCT04532164?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 137 participants. The study started on 2013-06-10. Estimated completion is 2013-11-11.
What conditions does trial NCT04532164 study?
This clinical trial studies the following conditions: Dermatitis, Photoallergic.
What interventions are being tested in trial NCT04532164?
The interventions under investigation include: Butenafine HCl 1% (BAY1896425) - Induction Phase (DRUG), Butenafine HCl 1% (BAY1896425) - Challenge Phase (DRUG).
Who is sponsoring clinical trial NCT04532164?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04532164 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.